VolitionRx Limited (NYSE American: VNRX), a multinational epigenetics company, announced a technical milestone with the successful detection of nucleosomes in capillary blood from critically ill patients with sepsis using a lateral flow finger-prick prototype. The study, conducted as part of the SUMMIT program, demonstrated the feasibility of detecting nucleosomes in capillary samples. The findings also support the feasibility of early detection of immune disruptions associated with conditions such as sepsis across point-of-care and non-laboratory settings.
The company said the prototype builds on prior results showing correlation between venous blood samples tested with its lateral flow system and its established Nu.Q nucleosome assay. Volition noted that this approach could expand access to testing through point-of-care use and broaden its addressable market while supporting future commercialization efforts, including potential partnerships to increase access in regions with limited laboratory infrastructure.
The ability to detect nucleosomes from a finger-prick sample represents a significant advancement in sepsis diagnostics. Sepsis, a life-threatening condition caused by the body's response to infection, requires rapid diagnosis for effective treatment. Traditional diagnostic methods often rely on venous blood samples and laboratory-based assays, which can delay results and limit access in resource-constrained settings. Volition's prototype aims to overcome these barriers by enabling testing at the point of care, potentially reducing turnaround times and improving patient outcomes.
This development aligns with Volition's mission to advance epigenetics for earlier detection and monitoring of life-altering diseases. The company's Nu.Q platform focuses on nucleosomes, which are DNA-protein complexes released into the bloodstream during cell death. Elevated nucleosome levels have been linked to various conditions, including cancer and sepsis. By demonstrating detection in capillary blood, Volition opens the door to simpler, more accessible testing methods.
The milestone is particularly relevant for regions with limited laboratory infrastructure, where finger-prick tests could facilitate earlier diagnosis and treatment. Volition plans to pursue partnerships to commercialize the prototype and expand its reach. The company's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.
For more details, the full press release is available at https://ibn.fm/ioEmu. Further information about Volition can be found on its website at www.Volition.com.
